Abstract: Prior to the 1990’s peritoneal malignancy was categorized as “carcinomatosis” with a general acceptance that nothing could be done for those unfortunate enough to have malignant involvement of the peritoneum. Since then, based on clinical research, the international oncology community believed that some selected cases who underwent comprehensive treatment centered on cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can not only acquire effective control of the disease, but also obtain clinical cure. Basingstoke and North Hampshire Hospital is one of the first centers to carry out basis and clinical research on peritoneal malignancy. Over the past 30 years, it has made historic contributions in the field of peritoneal malignancy and promoting the development of international collaborations. In March 1994, Basingstoke performed the first CRS under the guidance of Paul Sugarbaker and currently deliver >350 cases a year. In 1998, Basingstoke hospital organized the inaugural meeting of what is now Peritoneal Surface Oncology Group International (PSOGI). Basingstoke hospital has established a multidisciplinary team to develop and promote CRS + HIPEC treatment strategy, formulated pseudomyxoma peritonei (PMP) and malignant peritoneal mesothelioma (MPM) guidelines, and carried out clinical trials such as combined CRS and small bowel/modified multivisceral transplantation in the treatment of peritoneal malignancy. Basingstoke is proud to have been part of the foundation, development, and continuity of PSOGI and continues to do so.